Samjin Pharmaceuticals Co., Ltd. Share Price

Equities

A005500

KR7005500004

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 30/05/2024 BST 5-day change 1st Jan Change
19,140 KRW -0.31% Intraday chart for Samjin Pharmaceuticals Co., Ltd. -2.15% -11.39%

Financials

Sales 2021 250B 181M 14.22B Sales 2022 274B 198M 15.59B Capitalization 344B 249M 19.57B
Net income 2021 28.4B 20.54M 1.62B Net income 2022 21.89B 15.83M 1.25B EV / Sales 2021 1.48 x
Net Debt 2021 42.79B 30.94M 2.43B Net Debt 2022 82.85B 59.9M 4.71B EV / Sales 2022 1.56 x
P/E ratio 2021
11.4 x
P/E ratio 2022
14.8 x
Employees 586
Yield 2021
3.04%
Yield 2022
3.12%
Free-Float 45.28%
More Fundamentals * Assessed data
Dynamic Chart
Neurophet, Inc. announced that it has received KRW 1 billion in funding from Samjin Pharmaceuticals Co., Ltd. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on June 16, 2023. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on June 16, 2023. CI
Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback announced on June 16, 2023 has expired with 227,116 shares, representing 1.74% for KRW 4,996.59 million. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on March 24, 2023. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on March 24, 2023. CI
Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback announced on March 24, 2023, has expired with 228,833 shares, representing 1.73% for KRW 4,995.92 million. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on June 16, 2023. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on March 24, 2023. CI
Samjin Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
Samjin Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 2, 2022. CI
Samjin Pharmaceuticals Co., Ltd.'s Equity Buyback announced on December 2, 2022, has expired with 183,020 shares, representing 1.36% for KRW 4,993.50 million. CI
More news
1 day-0.31%
1 week-2.15%
Current month-3.33%
1 month-3.33%
3 months-6.63%
6 months-13.00%
Current year-11.39%
More quotes
1 week
19 000.00
Extreme 19000
19 560.00
1 month
19 000.00
Extreme 19000
19 950.00
Current year
19 000.00
Extreme 19000
21 850.00
1 year
19 000.00
Extreme 19000
24 450.00
3 years
19 000.00
Extreme 19000
30 500.00
5 years
15 900.00
Extreme 15900
33 850.00
10 years
15 900.00
Extreme 15900
64 900.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 -
Members of the board TitleAgeSince
Chairman 82 -
Chairman 82 -
Chief Executive Officer 67 -
More insiders
Date Price Change Volume
30/05/24 19,140 -0.31% 20 532
30/05/24 19,200 -0.78% 16,265
29/05/24 19,350 -0.62% 21,953
28/05/24 19,470 -0.31% 5,362
27/05/24 19,530 0.00% 15,196

End-of-day quote Korea S.E., May 30, 2024

More quotes
Samjin Pharmaceuticals co., LTD. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Company’s products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. It distributes its products to the hospitals and drugstores. The Company supplies its products within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A005500 Stock